

Individual and Family Plans

# **Botulinum Toxins**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
	Office Contact:
Date of Birth:	
Line of Business:   Exchange - P	
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):
REQUEST FOR EXPEDITED REVIEW: By on the enrollee or the enrollee's ability to regain	hecking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of a maximum function.
Drug Name:	
Strength:	
Directions / SIG:	
Please attach any pertinent i	nedical history including labs and information for this member that may support approval.  Please answer the following questions and sign.
04 1 11 1	
Q1. Is this a renewal requ	lest?
☐ Yes - go to 2	☐ No - go to 3
	as the prescriber provided medical documentation to support the need curring no sooner than every 3 months?
□Yes	□ No
documented diagnosis of	ESTS: Is the patient greater than or equal to 18 years of age with a overactive bladder (OAB) with symptoms of urge urinary incontinence ue to detrusor overactivity associated with a neurologic condition (e.g., e sclerosis)?
☐ Yes	□ No
•	nn inadequate response or intolerance to at least one anticholinergic nin / oxybutynin ER, tolterodine / tolterodine ER, trospium / trospium
☐ Yes	□ No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



Individual and Family Plans

# **Botulinum Toxins**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:			
Q5. Is the patient greater than or equal to 18 years of age with a documented diagnosis of migraine headaches occurring greater than or equal to 15 days per month with headache lasting 4 hours a day or longer?				
☐ Yes	□ No			
Q6. Has the patient had an inadequate response or intolerance to at least 2 different classes of prophylactic medications (i.e., beta blockers [such as propranolol, metoprolol], amitriptyline, topiramate, valproic acid or its derivatives, verapamil)?				
☐ Yes	□ No			
Q7. Does the patient have a documented diagnosis of sialorrhea associated with disorders of the nervous system or neurologic dysfunction?				
☐Yes	□ No			
Q8. Has the patient had an inadequate response or intolerance to at least 1 anticholinergic medication (e.g., glycopyrrolate)?				
☐ Yes	□ No			
Q9. Is the patient greater than or equal to 18 years of age with a documented diagnosis of severe primary axillary hyperhidrosis?				
☐ Yes	□ No			
Q10. Is the patient greater than or equal to 18 years of age with a documented diagnosis of upper limb spasticity where the drug is being used to decrease the severity of increased muscle tone [in elbow flexors (biceps), wrist flexors (flexor carpi radialis and flexor carpi ulnaris), finger flexors (flexor digitorum profundus and flexor digitorum sublimis), or thumb flexors (adductor pollicis and flexor pollicis longus)] or lower limb spasticity where the drug is being used to decrease the severity of increased muscle tone [in ankle or toe flexors (gastrocnemius, soleus, tibialis posterior, flexor hallucis longus, flexor digitorum longus, brachialis, brachioradialis, pronator teres, pronator quadratus, lumbricals, interossei, flexor pollicis brevis, and opponens pollicis)]?				
☐ Yes	□ No			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



Individual and Family Plans

# **Botulinum Toxins**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:			
Q11. Is the patient greater than or equal to 16 years of age with a documented diagnosis of cervical dystonia where the drug is being used to reduce the severity of abnormal head position and neck pain?				
☐ Yes	□ No			
Q12. Is the patient greater than or equal to 12 years of age with a documented diagnosis of blepharospasm or strabismus associated with dystonia?				
☐ Yes	□ No			
Q13. Does the patient have a documented diagnosis of spasticity associated with cerebral palsy, hemifacial spasm, or laryngeal dystonia?				
☐ Yes	□ No			
Q14. Is the prescribing physician a specialist for the condition (e.g., urologist for OAB or urinary incontinence; neurologist for migraine headaches; neurologist or physiatrist for upper limb spasticity, cervical dystonia, or hyperhidrosis; ophthalmologist for blepharospasm or strabismus)?				
☐Yes	□ No			
Q15. Has the prescriber submitted documentation of the proposed injection site(s) and the dose that will be injected into each site?				
☐ Yes	□ No			
Q16. Is the dose in accordance with the recommend dosing below and occurring no sooner than every 3 months? Overactive bladder – up to 100 units per treatment; Urinary incontinence – up to 200 units per treatment; Chronic migraine – up to 155 units per treatment; Upper limb spasticity – up to 400 units per treatment; Cervical dystonia – up to 300 units per treatment (up to 50 units per site); Hyperhidrosis – up to 100 units per treatment (up to 50 units per axilla); Blepharospasm – up to 200 units per treatment; Strabismus – up to 25 units per muscle per injection				
☐ Yes	□ No			
Q17. Additional Information:				

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



Individual and Family Plans

# **Botulinum Toxins**

Fax back to: (833) 605-4407 Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

TELACE NOTE. Any information (patient, prescriber, drug, labe) left blank, megible, or not attached with delay the review process.				
Patient Name:		Prescriber Name:		
Prescriber Signatur	e		 Date	
			2024 Prior Authorization Request	